High Cholesterol: New Reporting Changes for Better Heart Risk Diagnosis
- ROME (April 1, 2025) – More than one in four Italians grapple with hypercholesterolemia, a condition that places a notable burden on the nation's health system, costing an...
- The joint document outlines several key recommendations to improve the identification and management of hypercholesterolemia:
- This proposed shift represents a significant change in how lipid profiles are reported,aiming to improve the identification of hypercholesterolemia,a major contributor to ischemic heart disease affecting approximately 5...
Italian Health Experts Advocate for Enhanced Hypercholesterolemia Reporting
Table of Contents
- Italian Health Experts Advocate for Enhanced Hypercholesterolemia Reporting
ROME (April 1, 2025) – More than one in four Italians grapple with hypercholesterolemia, a condition that places a notable burden on the nation’s health system, costing an estimated 1.14 billion euros annually. In response, the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBiOC) have jointly released a document proposing an integrated reporting system for the condition.
Key Recommendations for Integrated Reporting
The joint document outlines several key recommendations to improve the identification and management of hypercholesterolemia:
- Automatic reporting of critical values, such as C-Clon greater than 190 mg/dL or triglycerides greater than 890 mg/dL, which may indicate familial hypercholesterolemia or risk of pancreatitis.
- Inclusion of additional parameters like Non-HDL,Remnants,Lp(a),and APO B for a more precise risk assessment,aligning with current scientific guidelines.
- Integration of LDL cholesterol target values within reports, tailored to individual cardiovascular risk categories.
- Allowing lipid profile testing without fasting, increasing accessibility to screening in various settings.
This proposed shift represents a significant change in how lipid profiles are reported,aiming to improve the identification of hypercholesterolemia,a major contributor to ischemic heart disease affecting approximately 5 million Italians.
Hypercholesterolemia’s Widespread Impact
Data from the Italian Health Examination Survey indicates that over 25% of the population has hypercholesterolemia,with a higher prevalence among women than men. However, only 18.3% self-report the condition, according to the passi observatory, suggesting a lack of awareness. Furthermore,nearly half of Italians do not recognize the dangers of LDL cholesterol,and one in three believe hypercholesterolemia is only a concern for those with pre-existing heart conditions.
Adding to the concern, a recent analysis indicates that hypercholesterolemic patients often fall into a medium-to-high cardiometabolic risk category, representing 50.1% of the working-age population (40-69 years).
Economic Implications of Hypercholesterolemia Management
Effective management of LDL cholesterol is crucial not only for health but also for economic sustainability. The annual cost of care for a patient with poorly managed hypercholesterolemia ranges from 4,200 to 5,000 euros, compared to around 2,900 euros for those achieving recommended therapeutic levels. Hospitalizations for avoidable complications and cardiovascular events account for approximately 60% of these expenses. Subsequent events lead to even higher costs, primarily due to re-hospitalizations.
Moreover, among patients in secondary prevention – those who have already experienced a cardiovascular event – over 80% still do not reach the LDL cholesterol target of less than 55mg/dL, as recommended by the latest EAS/ESC guidelines.
Adherence to lipid-lowering therapies remains a challenge,with only 44% of patients correctly following their treatment,and adherence decreasing with age. However, increased adherence can reduce total costs by up to 38% by preventing major cardiovascular events like stroke and heart attack.
Personalized LDL Cholesterol Targets
Current scientific evidence suggests that even a modest reduction in LDL cholesterol levels, achieved through early diagnosis and targeted treatment, can substantially lower the risk of myocardial infarction and cardiovascular death. A key issue is that many reports still present standardized “reference values” based on population averages, rather than “decision-making values” tailored to individual cardiovascular risk. This can be misleading, as a “standard” value may be critical for a high-risk patient, potentially leading to inappropriate suspension of lipid-lowering therapies or underestimation of conditions like familial hypercholesterolemia.
Call for System Adjustment
SIC and SIBiOC advocate for a revised approach aligned with European guidelines (ESC/EAS) to improve the reporting system, providing clinicians and patients with a clear, accessible, and integrated view of lipid values.
Hypercholesterolemia is a significant health concern with serious public health implications,” said Sen. Elena Murelli, a promoter of parliamentary initiatives for cardio, cerebro, and vascular diseases. “High cholesterol promotes the formation of atherosclerotic plaques, increasing the risk of myocardial infarction, stroke, and peripheral artery diseases. Clearer reporting of cardiovascular risk will enable prompt intervention,reducing cardiovascular events and benefiting both public health and the sustainability of the national health service.
Murelli estimates that treating cardiovascular diseases linked to hypercholesterolemia costs 1.14 billion euros annually, including hospitalizations, medications, and surgery. Addressing hypercholesterolemia effectively will reduce the burden of cardiovascular diseases, improve public health, and enhance the health system’s sustainability.
Cyrus Indolfi, president of the Italian Federation of Cardiology, emphasized the importance of reducing risk factors, stating, It is now confirmed that high levels of LDL cholesterol have a causal role in acute myocardial infarction, one of the main causes of death in italy. Reducing LDL cholesterol means reducing the risk of cardiovascular events. For this reason, it is essential to strengthen prevention, promoting screening campaigns capable of identifying people at medium-high risk early and promptly start them.
Pasquale Perrone Filardi, president of the Italian Cardiology Society, noted, It is necessary to make citizens and patients understand that there is no LDL cholesterol value that goes well for everyone. The target level depends on the cardiovascular risk profile of each patient: the higher the risk, the lower the value to be achieved to reduce the probability of cardiovascular events.
Marcello Ciaccio, president of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, added, The joint document between the Italian Cardiology Society and the Italian Society of Clinical Biochemistry – Laboratory Medicine represents a fundamental step towards an accurate, effective and clinically useful laboratory reporting. The document underlines the importance of a close integration between laboratory medicine and clinical medicine to ensure that the results of the laboratory exams are not only numerical data, but interpretative tools contextualized in the clinical reality of the citizen/patient.
Here’s a Q&A-style blog post crafted from teh provided article, optimized for user engagement and search engines:
Decoding Hypercholesterolemia: A Guide to Understanding and Managing High Cholesterol
Introduction:
High cholesterol, or hypercholesterolemia, is a notable health concern, affecting millions. This article, inspired by the recent recommendations from Italian health experts, aims to clarify what hypercholesterolemia is, why its a problem, and how improved reporting and management can make a difference in your health. We’ll explore the core issues in a question-and-answer format,making the information clear and easy to understand.
what is Hypercholesterolemia?
Q: What exactly is hypercholesterolemia?
A: Hypercholesterolemia is simply the medical term for having high cholesterol in your blood. Cholesterol is a type of fat (lipid) that’s essential for building healthy cells. However, having too much of certain types can increase your risk of heart disease and stroke.
Q: What are the different types of cholesterol?
LDL (Low-Density Lipoprotein) Cholesterol (The “Bad” Cholesterol): This is the primary type of cholesterol that contributes to plaque buildup in your arteries. High levels of LDL cholesterol increase your risk of heart disease and stroke.
HDL (High-Density Lipoprotein) Cholesterol (the “Good” Cholesterol): HDL helps remove LDL cholesterol from your arteries. Higher levels of HDL cholesterol are associated with a lower risk of heart disease.
Triglycerides: another type of fat found in your blood. High triglyceride levels can also increase your risk of heart disease.
Non-HDL Cholesterol: This is a calculation that includes all the “bad” forms of cholesterol—the LDL plus other harmful particles in the blood, like VLDL, IDL.
Q: Is hypercholesterolemia a common problem?
A: Yes, it is indeed. in Italy,over 25% of the population has hypercholesterolemia,and the numbers are similar in many other countries. This means a significant portion of the population is at increased risk for cardiovascular complications.
Understanding the Risks and Consequences
Q: why is hypercholesterolemia a serious health concern?
A: High cholesterol, notably high LDL cholesterol, contributes to the buildup of plaque in your arteries (atherosclerosis).This plaque can narrow your arteries, making it harder for blood to flow. This can lead to serious health problems like:
Heart attack (myocardial infarction)
Stroke
Peripheral artery disease
Angina (chest pain)
Q: What are the symptoms of hypercholesterolemia?
A: Hypercholesterolemia frequently enough has no symptoms in its early stages. This is why regular cholesterol checks (lipid profiles) are so crucial. The first sign might potentially be a heart attack or stroke, highlighting the necessity of early detection and management.
Q: What’s the impact of hypercholesterolemia on the Italian health system?
A: Hypercholesterolemia places a significant burden on Italy’s healthcare system, costing an estimated 1.14 billion euros annually. this includes expenses from hospitalizations, medications, and surgeries due to cardiovascular events. This underscores the importance of effective screening and treatment programs to reduce healthcare costs.
The Call for Improved Reporting
Q: What’s the proposal being made by the Italian Society of Cardiology (SIC) and the Italian Society of clinical Biochemistry and Clinical Molecular Biology (SIBiOC)?
A: They are advocating for an integrated reporting system for lipid profiles (cholesterol tests). This means a more comprehensive and informative way for doctors and patients to understand their cholesterol levels and associated risks. The goal is to improve early detection and management.
Q: What are the key recommendations for the new reporting system?
A: The primary recommendations include:
Automatic Reporting of Critical Values: Critical values such as C-Clon levels greater than 190 mg/dL or triglycerides greater than 890 mg/dL should be automatically reported to alert about potential serious issues like familial hypercholesterolemia or risk of pancreatitis.
Inclusion of Additional Parameters: Reports should include parameters like Non-HDL,Remnants,Lp(a),and APO B for more precise risk assessments.
Integration of LDL Cholesterol targets: LDL cholesterol targets, tailored to individual cardiovascular risk, should be clearly displayed within the reports.
Fasting Not Required: Allowing lipid profile testing without fasting, to increase accessibility.
Q: Why is this new reporting system so significant?
A: The current system often only presents “reference values” based on population averages. The proposed system aims to incorporate “decision-making values” specifically tailored to a specific patient’s individual cardiovascular risk, which will ensure that the need for treatment is more immediately and effectively communicated.
Understanding Individual Risk and Management
Q: Are there different LDL cholesterol targets?
A: Yes, absolutely.The “target” LDL cholesterol level is not the same for everyone. It depends on your overall cardiovascular risk. Those with a higher risk (e.g.,history of heart disease,diabetes,family history) need to aim for lower LDL levels.
Q: What are the general risk categories? What are associated LDL targets?
A: There are many versions of this.Here is one example:
Very High Risk: Includes people with established cardiovascular disease, high risk scores. LDL target less than 55 mg/dL.
High Risk: Includes people with multiple risk factors, or other considerations. LDL target less than 70 mg/dL.
Moderate Risk: Includes people with one or more risk factors. LDL target less than 100 mg/dL.
It’s important to discuss your individual risk profile and goals with your doctor.
Q: How can I lower my LDL cholesterol levels?
A: There are several strategies:
Lifestyle Changes: Include a heart-healthy diet (low in saturated and trans fats), regular exercise, maintaining a healthy weight, and not smoking.
Medications: Statins, and other lipid-lowering drugs are frequently prescribed to bring down LDL-cholesterol levels.
Treatment Adherence: Ensure you adhere to treatment as best as possible.
Q: What specific lifestyle changes can help lower cholesterol?
A:
Diet:
Reduce saturated fats (found in red meat, processed meats, and full-fat dairy).
Eliminate trans fats (frequently enough found in processed foods and fried foods).
Increase soluble fiber (found in oats, beans, fruits, and vegetables).
Eat foods rich in omega-3 fatty acids (found in fatty fish like salmon and tuna).
exercise regularly. Aim for at least 150 minutes of moderate-intensity exercise per week.
Maintain a healthy weight.
Quit smoking.
Q: How important is it to stick to my prescribed treatment (e.g., medication)?
A: very important. Adherence to lipid-lowering therapies is crucial. Regrettably,only 44% of patients with hypercholesterolemia correctly follow their treatment.This is where adherence to the recommended lifestyle, and any drug treatments, can have the biggest positive impacts on health outcomes. Studies show increased adherence can reduce total costs by up to 38%, highlighting the considerable impact of patient participation.
The Big Picture: Prevention and Sustainability
Q: What are the economic implications if hypercholesterolemia isn’t managed effectively?
A: The annual cost of care for patients with poorly managed hypercholesterolemia is significantly higher (4,200-5,000 euros) compared to that for those who are at their therapeutic goals (2,900 euros). Hospitalizations for avoidable complications account for around 60% of these increased expenses. Effective management of LDL cholesterol is, therefore, essential for both health and economic sustainability.
Q: What is the broader message from the Italian health experts?
A: The message is clear: early detection, personalized treatment, and patient education are critical to battling hypercholesterolemia. They want patients and the medical community to recognize that high cholesterol is not just a concern for people with pre-existing heart problems. Improved reporting, tailored targets, and increased awareness can lead to better outcomes, a healthier population, and reduced strain on healthcare resources.